Galderma announced the launch of Sculptra in China. The first regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCA) formulation was approved by China’s National Medical Products Administration for correcting mid-facial volume loss and/or contour deficiencies last year. The approval was based on results from a study in China, which showed Sculptra’s ability to achieve high and maintained response rates in the correction of midface volume/contour deficit through to two years, building on its 25 years of clinical evidence. 

“Sculptra has a unique and rich history spanning over 25 years, and its launch in China signals the start of another chapter in its incredible journey," Baldo Scassellati Sforzolini, M.D., Ph.D., global head of R&D at Galderma, said in a release. "Patients and healthcare professionals in China will now have access to a premium product, backed by decades of clinical evidence, which can help them achieve their varied aesthetic needs by offering long-lasting and natural-looking results.”  

China is a major market for Galderma, where sales have fueled the company’s strong performance across product categories. The aesthetics industry in China has also experienced remarkable growth in recent years, driven by increasing consumer demand for beauty and wellness treatments. The market is expected to continue expanding at a rate of up to 15% in the coming years, and research has shown that many Chinese consumers prioritize the safety and outcomes of their aesthetic treatments. Sculptra is well placed to meet these expectations as its extensive safety profile and high satisfaction rate has been demonstrated in more than 10,000 patients in clinical studies over 25 years.

This launch further expands Sculptra’s global reach, which already spans over 40 countries and regions worldwide, and underscores Galderma’s commitment to meeting the diverse patient needs and beauty standards across different parts of the world. As the pure-play dermatology category leader, Galderma’s story is one of continuous growth, and it is committed to bringing innovative aesthetics solutions to patients across the world.